Skip to main content
. 2003 May 1;111(9):1329–1338. doi: 10.1172/JCI16750

Figure 8.

Figure 8

MOR agonists prevent histologic colitis in reconstituted SCID mice. (a) Histologic scores (mean ± SEM) evaluated 4 weeks after T cell transfer in control SCID mice reconstituted with both CD4+CD45RBlo and CD45RBhi T cells (Hi + Lo) and in SCID mice with colitis reconstituted with CD4+CD45RBhi T cells without any treatment (Hi) or after subcutaneous administration of DALDA (10–2 mg/kg/d) (Hi + D) or DAMGO (10–3 mg/kg/d) (Hi + Do). (b–d) Representative histologic sections of the colon in control SCID mice after CD4+CD45RBlo and CD45RBhi T cell transfer (control) (b) and in SCID mice with colitis reconstituted with CD4+CD45RBhi T cells without any treatment (RBhi) (c) or after subcutaneous administration of DALDA (10–2 mg/kg/d) (RBhi + DALDA) (d). ×250.